FDA Sends Sutent sNDA For Pancreatic Cancer To ODAC
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs Advisory Committee's April 12 review may have been spurred by any number of issues in the Phase III trial, including its early termination, reliability of progression-free survival assessments and failure to show quality-of-life improvements.